glp 1 and sarcopenia Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? 𧬠New study from #NYCU
Description
Ask your pharmacist
(Reasons 2-4, at rates described in 5, in the manner described in 7.) Dont make this mistake
Work in the Trapp laboratory is supported by the Medical Research Council (MRC) (MR/N02589X/1), the National Institutes of Health (NIH) and the European Foundation for the Study of Diabetes (EFSD)
They may face new restrictions
